Kinnate Biopharma (KNTE): Price and Financial Metrics


Kinnate Biopharma (KNTE): $7.53

0.23 (+3.15%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add KNTE to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

KNTE Stock Price Chart Interactive Chart >

Price chart for KNTE

KNTE Price/Volume Stats

Current price $7.53 52-week high $15.86
Prev. close $7.30 52-week low $5.17
Day low $7.25 Volume 149,987
Day high $7.79 Avg. volume 108,479
50-day MA $6.70 Dividend yield N/A
200-day MA $9.83 Market Cap 332.56M

Kinnate Biopharma (KNTE) Company Bio


Kinnate Biopharma, Inc. operates as a biopharmaceutical company, which engages in the research and development of Kinnate Discovery Engine that targets genomic drivers of cancer. The company was founded by Stephen W. Kaldor and Eric A. Murphy in January 2018 and is headquartered in San Diego, CA.


KNTE Latest News Stream


Event/Time News Detail
Loading, please wait...

KNTE Latest Social Stream


Loading social stream, please wait...

View Full KNTE Social Stream

Latest KNTE News From Around the Web

Below are the latest news stories about KINNATE BIOPHARMA INC that investors may wish to consider to help them evaluate KNTE as an investment opportunity.

Kinnate Biopharma Inc. to Present Trials in Progress Poster for its Pan-FGFR Inhibitor, KIN-3248, at the 2023 ASCO Gastrointestinal Cancers Symposium and ASCO Genitourinary Cancers Symposium

SAN FRANCISCO and SAN DIEGO, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced the poster presentation of the design and rationale of a Phase 1 trial-in-progress (KN-4802, NCT05242822) evaluating the Company’s investigational pan-FGFR inhibitor, KIN-3248, at two upcoming American Society of Clinical Oncology (ASCO)-related conferences. KIN-3248 is an irreversible, small molecule pan-FGFR inhibitor des

Yahoo | January 17, 2023

We're Not Very Worried About Kinnate Biopharma's (NASDAQ:KNTE) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Yahoo | January 12, 2023

Kinnate Biopharma dips after Stifel downgrade (NASDAQ:KNTE)

Kinnate Biopharma (KNTE) shares fell 15% in Thursday''s trading after Stifel Nicolaus downgraded the stock from Buy to Hold.Analyst Benjamin Burnett raised questions over the the…

Seeking Alpha | November 17, 2022

Kinnate Biopharma Inc. Announces Third Quarter 2022 Financial Results and Recent Corporate Updates

SAN FRANCISCO and SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc . (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced financial results for the quarter ended September 30, 2022, and recent corporate updates.

GlobeNewswire | November 10, 2022

Kinnate Biopharma GAAP EPS of -$0.70 misses by $0.10 (NASDAQ:KNTE)

Kinnate Biopharma press release (KNTE): Q3 GAAP EPS of -$0.70 misses by $0.10.Cash and Cash Equivalents and Investments Position: As of September 30, 2022, the total of cash and…

Seeking Alpha | November 10, 2022

Read More 'KNTE' Stories Here

KNTE Price Returns

1-mo 23.44%
3-mo -11.31%
6-mo -40.19%
1-year -31.42%
3-year N/A
5-year N/A
YTD 23.44%
2022 -65.58%
2021 -55.46%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.564 seconds.